Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ranibizumab injection alone Clear all
Completed Phase 2 Interventional Results available

Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)

NCT01397409
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
AGN-150998, ranibizumab, Sham Injection
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 2, 2026, 5:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lucentis for Treatment of Macular Edema

NCT00464581
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Not listed
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
Up to 90 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema

NCT00444600
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Triamcinolone Acetonide + laser, Ranibizumab + laser, Sham injection + laser, Ranibizumab + deferred laser
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
50
States / cities
Artesia, California • Beverly Hills, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

NCT01489189
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Prompt Panretinal Photocoagulation, 0.5-mg Ranibizumab, Deferred panretinal photocoagulation
Other · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
48
States / cities
Phoenix, Arizona • Loma Linda, California • Palm Springs, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 2, 2026, 5:20 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy

NCT01248117
View directory record Official record
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
ranibizumab 2.0mg
Drug
Lead sponsor
Retina Consultants of Hawaii
Other
Eligibility
25 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Honolulu, Hawaii • ‘Aiea, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 25, 2010 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema

NCT02699450
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Faricimab, Ranibizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
60
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD

NCT01414153
View directory record Official record
Conditions
Exudative Age-related Macular Degeneration
Interventions
4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea, sham injection
Drug
Lead sponsor
Lpath, Inc.
Industry
Eligibility
50 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
44
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 2, 2026, 5:20 AM EDT
Completed No phase listed Observational

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

NCT05146687
View directory record Official record
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Aflibercept, Ranibizumab, Bevacizumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
369,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 2, 2026, 5:20 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

NCT01994291
View directory record Official record
Conditions
Macular Edema, Diabetic
Interventions
Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)

NCT00492284
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
verteporfin, ranibizumab, dexamethasone
Drug
Lead sponsor
QLT Inc.
Industry
Eligibility
50 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
21
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2011 · Synced Oct 2, 2026, 5:20 AM EDT
Not listed Not applicable Interventional

Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD

NCT00455871
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
reduced fluence photodynamic therapy with Visudyne, Lucentis
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 9, 2008 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)

NCT00424710
View directory record Official record
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
ranibizumab intravitreal injection
Drug
Lead sponsor
Hawaii Pacific Health
Other
Eligibility
25 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Honolulu, Hawaii • ‘Aiea, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 2, 2026, 5:20 AM EDT
Terminated Phase 2 Interventional Results available

The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration

NCT00857259
View directory record Official record
Conditions
Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration
Interventions
Everolimus, Ranibizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
4
States / cities
Beverly Hills, California • Sacramento, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study

NCT00407381
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab, Laser photocoagulation
Drug · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab

NCT03340610
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Alflibercept
Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 2 Interventional

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

NCT03345082
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
OPT-302, ranibizumab, sham intravitreal injection
Biological · Other
Lead sponsor
Opthea Limited
Industry
Eligibility
50 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
55
States / cities
Phoenix, Arizona • Beverly Hills, California • Encino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 2, 2026, 5:20 AM EDT
Completed No phase listed Observational

Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.

NCT01942213
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Not listed
Lead sponsor
Prism Vision Group
Other
Eligibility
65 Years to 90 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration

NCT01157065
View directory record Official record
Conditions
Exudative Age-Related Macular Degeneration
Interventions
AL-78898A, Ranibizumab
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 2, 2026, 5:20 AM EDT